Dear PAGE participants,
We have only a few places available for the LAP&P TMDD case study. So if you would like to join this course, please register now! During the course, we will discuss the importance of understanding the pharmacology of monoclonal antibodies (mAbs) to make the right decisions in target-mediated drug disposition (TMDD) model development. We will learn more on; 1) the relevance of mechanistic modelling for mAbs, 2) the considerations with regards to scaling the model for first in human (FIH) approaches, and 3) what TMDD models are, what approximations may be applicable and how to use these models for (non-) clinical data. LAP&P's interactive course will be held on Tuesday the 27th of June 2023 (9:00 - 17:00) in A Coruña, Spain. After a short introduction, we will directly dive into a hands-on session, in which the participants work in small groups on TMDD modelling challenges using a nlmixr2 within a shinyMixR workflow. Find more information and register for the course on https://lapp.nl/lapp-page-course. Kind regards, Tamara van Steeg Tamara van Steeg, PhD Principal Consultant, Director of Research LAP&P Consultants Archimedesweg 31, 2333 CM Leiden The Netherlands Web: www.lapp.nl<http://www.lapp.nl/>
